AR105758A1 - Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidona - Google Patents
Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidonaInfo
- Publication number
- AR105758A1 AR105758A1 ARP160100825A ARP160100825A AR105758A1 AR 105758 A1 AR105758 A1 AR 105758A1 AR P160100825 A ARP160100825 A AR P160100825A AR P160100825 A ARP160100825 A AR P160100825A AR 105758 A1 AR105758 A1 AR 105758A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- losartan
- pharmaceutical formulation
- mixture
- salts
- Prior art date
Links
- 239000002083 C09CA01 - Losartan Substances 0.000 title abstract 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004773 losartan Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 AMLODIPINA Substances 0.000 title 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- 239000000654 additive Substances 0.000 abstract 4
- 230000000996 additive effect Effects 0.000 abstract 4
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 2
- 229960000528 amlodipine Drugs 0.000 abstract 2
- 229960001523 chlortalidone Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica compleja para prevenir o tratar las enfermedades cardiovasculares, donde la formulación comprende: una primera mezcla que incluye amlodipina o una de sus sales aceptables desde el punto de vista farmacéutico, clortalidona o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico; y una segunda mezcla que incluye losartan o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico, en donde la primera mezcla y la segunda mezcla están presentes en una forma separada físicamente una de la otra. Reivindicación 11: Un método para preparar una formulación farmacéutica compleja para prevenir o tratar las enfermedades cardiovasculares, donde el método comprende los pasos de: a) mezclar amlodipina o una de sus sales aceptables desde el punto de vista farmacéutico, clortalidona o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico; y b) mezclar losartan o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150045645A KR101914930B1 (ko) | 2015-03-31 | 2015-03-31 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105758A1 true AR105758A1 (es) | 2017-11-08 |
Family
ID=57007292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100825A AR105758A1 (es) | 2015-03-31 | 2016-03-29 | Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidona |
Country Status (11)
Country | Link |
---|---|
KR (1) | KR101914930B1 (es) |
CN (1) | CN108289850B (es) |
AR (1) | AR105758A1 (es) |
JO (1) | JO3461B1 (es) |
MX (1) | MX2017012459A (es) |
MY (1) | MY190016A (es) |
PH (1) | PH12017501769B1 (es) |
RU (1) | RU2713883C2 (es) |
TW (1) | TWI714560B (es) |
UY (1) | UY36595A (es) |
WO (1) | WO2016159535A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101910902B1 (ko) * | 2016-11-03 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 |
KR20180053044A (ko) * | 2016-11-11 | 2018-05-21 | 주식회사유한양행 | 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법 |
KR20200143914A (ko) * | 2019-06-17 | 2020-12-28 | 주식회사유한양행 | 암로디핀 또는 이의 염 및 클로르탈리돈 또는 이의 염을 포함하는 다층 정제 형태의 약학 조성물 |
KR20210074428A (ko) | 2019-12-11 | 2021-06-22 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 |
CN115666564B (zh) * | 2020-06-09 | 2024-07-16 | 韩美药品株式会社 | 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
AU685898B2 (en) | 1993-12-23 | 1998-01-29 | Du Pont Merck Pharmaceutical Company, The | Polymorphs of losartan and the process for the preparation of form II of losartan |
KR100452491B1 (ko) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
EP1648515B1 (en) * | 2003-07-16 | 2012-11-21 | Boehringer Ingelheim International GmbH | Chlorthalidone combinations |
US20070237815A1 (en) * | 2006-04-06 | 2007-10-11 | Lawrence Solomon | Dosage forms and methods comprising amlodipine and chlorthalidone |
KR101247583B1 (ko) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물 |
KR20090057538A (ko) * | 2007-12-03 | 2009-06-08 | 박사룡 | 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물 |
WO2009084040A1 (en) * | 2007-12-28 | 2009-07-09 | Rubicon Research Private Limited | Once a day formulation of angiotensin receptor blockers |
NZ594738A (en) | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
KR101907881B1 (ko) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 |
KR101392364B1 (ko) * | 2012-04-17 | 2014-05-07 | 한국유나이티드제약 주식회사 | 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물 |
-
2015
- 2015-03-31 KR KR1020150045645A patent/KR101914930B1/ko active IP Right Grant
-
2016
- 2016-03-11 WO PCT/KR2016/002437 patent/WO2016159535A1/en active Application Filing
- 2016-03-11 CN CN201680020057.5A patent/CN108289850B/zh active Active
- 2016-03-11 RU RU2017134562A patent/RU2713883C2/ru active
- 2016-03-11 MY MYPI2017703447A patent/MY190016A/en unknown
- 2016-03-11 MX MX2017012459A patent/MX2017012459A/es unknown
- 2016-03-18 TW TW105108523A patent/TWI714560B/zh not_active IP Right Cessation
- 2016-03-27 JO JOP/2016/0058A patent/JO3461B1/ar active
- 2016-03-29 AR ARP160100825A patent/AR105758A1/es not_active Application Discontinuation
- 2016-03-30 UY UY0001036595A patent/UY36595A/es not_active Application Discontinuation
-
2017
- 2017-09-26 PH PH12017501769A patent/PH12017501769B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI714560B (zh) | 2021-01-01 |
UY36595A (es) | 2016-10-31 |
CN108289850A (zh) | 2018-07-17 |
KR101914930B1 (ko) | 2018-11-05 |
PH12017501769A1 (en) | 2018-03-19 |
WO2016159535A1 (en) | 2016-10-06 |
TW201639563A (zh) | 2016-11-16 |
KR20160117055A (ko) | 2016-10-10 |
RU2017134562A (ru) | 2019-04-04 |
JO3461B1 (ar) | 2020-07-05 |
MY190016A (en) | 2022-03-22 |
PH12017501769B1 (en) | 2018-03-19 |
RU2713883C2 (ru) | 2020-02-10 |
MX2017012459A (es) | 2018-01-30 |
CN108289850B (zh) | 2021-04-09 |
RU2017134562A3 (es) | 2019-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
DK3331864T3 (da) | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse | |
CR20180564A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
AR105758A1 (es) | Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidona | |
CO2017004535A2 (es) | Péptidos macrocíclicos que inhiben las interacciones proteína/proteína pd-1/pd-l1 y cd80/pdl1 | |
CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
DK3442973T3 (da) | Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme | |
EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
UY36660A (es) | Combinaciones de inhibidores de irak4 | |
DK3328844T3 (da) | 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme | |
AR103895A1 (es) | Lactamas como inhibidores de rock | |
CR20160538A (es) | Combinación | |
MA43402A (fr) | Composition pharmaceutique comprenant un inhibiteur puissant d'urat1 | |
SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
CO2019003162A2 (es) | Formas cristalinas y salinas de compuestos agonistas de ppar | |
DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
BR112017023225A2 (pt) | inibidor de proteína cinase | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
CL2019001804A1 (es) | Activador de nrf2. | |
CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |